Page last updated: 2024-11-04

risedronic acid and Atherogenesis

risedronic acid has been researched along with Atherogenesis in 1 studies

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Research Excerpts

ExcerptRelevanceReference
"Thirteen Japanese type 2 diabetes postmenopausal women with newly diagnosed osteoporosis (osteoporosis group) and 13 age- and weight-matched diabetic women with normal bone mineral density (control group) were enrolled in this 1-year prospective study."1.36Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. ( Hayashi, K; Kanazawa, I; Shimizu, T; Sugimoto, T; Takase, H; Yamaguchi, T, 2010)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kanazawa, I1
Yamaguchi, T1
Hayashi, K1
Takase, H1
Shimizu, T1
Sugimoto, T1

Other Studies

1 other study available for risedronic acid and Atherogenesis

ArticleYear
Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis.
    The American journal of the medical sciences, 2010, Volume: 339, Issue:6

    Topics: Aged; Aorta, Abdominal; Atherosclerosis; Body Mass Index; Bone Density Conservation Agents; Calcinos

2010